Vistagen Therapeutics Analyst Price Targets - Benzinga

Vistagen Therapeutics Inc

VTGNNASDAQ

Trade with Public

Trade with Public

$0.2730

-0.022-7.46%

가까이에: Sep 25, 5:00 PM EST

$0.2620

-0.011-4.03%

시간외: 7:57 PM EST

PRO

변동 이유?:Vistagen shares are trading lower. The company announced it presented explo...

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Vistagen Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vistagen Therapeutics (VTGN).

Price Target Range — 2 Quarters

Analyst Consensus — 4 Analysts

1Buy

3Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$6Upside to Avg. PT+2361.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Dec 17, 2025	William Blair	Tim Lugo	Downgrade	Outperform→Market Perform	—
Dec 17, 2025	Maxim Group	Jason McCarthy	Downgrade	Buy→Hold	—
Dec 17, 2025	Jefferies	Andrew Tsai	Downgrade	Buy→Hold	$15→$1
Dec 7, 2023	Jefferies	Andrew Tsai	Upgrade	Hold→Buy	$0→$15
Nov 14, 2023	Stifel	Paul Matteis	Initiate	Buy	$12

More with Benzinga EdgeGet Access

Analyst Ratings News

Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data

Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.

Vandana Singh

PRO
William Blair Downgrades Vistagen Therapeutics to Market Perform

William Blair analyst Tim Lugo downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Outperform to Market Perform.

Benzinga Newsdesk

PRO
Maxim Group Downgrades Vistagen Therapeutics to Hold

Maxim Group analyst Jason McCarthy downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Buy to Hold.

Benzinga Newsdesk

PRO
Jefferies Downgrades Vistagen Therapeutics to Hold, Lowers Price Target to $0.9

Jefferies analyst Andrew Tsai downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Buy to Hold and lowers the price target from $15 to $0.9.

Benzinga Newsdesk

All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

Zacks

PRO
Jefferies Upgrades Vistagen Therapeutics to Buy, Raises Price Target to $15

Jefferies analyst Andrew Tsai upgrades Vistagen Therapeutics (NASDAQ:VTGN) from Hold to Buy and raises the price target from $0.2 to $15.

Benzinga Newsdesk